Download PDF
Thromb Haemost
DOI: 10.1055/a-2510-6370
Invited Clinical Focus

Heterogeneity in American and European Peripheral Artery Disease Guidelines on Non-statin Lipid-Lowering Therapy and Rivaroxaban

Mehrdad Zarghami
1   Department of Medicine, Jamaica Hospital Medical Center, Queens, New York, United States
2   Division of Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
,
Sina Rashedi
3   Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
,
Gregory Piazza
2   Division of Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
3   Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
,
Marie Denise Gerhard-Herman
2   Division of Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
,
Geoffrey D. Barnes 
4   Frankel Cardiovascular Center, University of Michigan Ann Arbor, Michigan, United States
,
Behnood Bikdeli
2   Division of Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
3   Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
5   YNHH/Yale Center for Outcomes Research and Evaluation (CORE), New Haven, Connecticut, United States
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

New guidelines of the American College of Cardiology and the American Heart Association (ACC/AHA)[1] and the European Society of Cardiology (ESC)[2] for peripheral artery disease (PAD) present comprehensive frameworks for management. Although both guidelines share thoughtful recommendations based on a review of randomized controlled trials (RCTs), noteworthy discrepancies exist regarding the recommended pharmacotherapies for PAD. We focus on two such areas: Adding non-statin lipid-lowering agents[3] [4] and incorporating low-dose rivaroxaban.[5] [6] [7] [8] We reflect on issues about the selection and interpretation of studies in these guidelines and the opportunity to improve aligning the recommendations with the current best evidence.



Publication History

Received: 14 November 2024

Accepted: 06 January 2025

Accepted Manuscript online:
07 January 2025

Article published online:
24 January 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Gornik HL, Aronow HD, Goodney PP. et al; Writing Committee Members. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2024; 83 (24) 2497-2604
    CrossrefPubMedSearch in Google Scholar
  • 2 Mazzolai L, Teixido-Tura G, Lanzi S. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 2024; 45 (36) 3538-3700
    CrossrefPubMedSearch in Google Scholar
  • 3 Paciullo F, Momi S, Gresele P. PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention. Thromb Haemost 2019; 119 (03) 359-367
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Ortega-Paz L, Franchi F, Angiolillo DJ. The lipid-platelet interplay: unraveling the effects of PCSK9 inhibition on platelet reactivity. Thromb Haemost 2024; 124 (06) 528-532
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Bauersachs R, Zannad F. Rivaroxaban: a new treatment paradigm in the setting of vascular protection?. Thromb Haemost 2018; 118 (S 01): S12-S22
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Galli M, Franchi F, Rollini F. et al. Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease. Thromb Haemost 2022; 122 (08) 1341-1351
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Weitz JI, Angiolillo DJ, Geisler T, Heitmeier S. Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence. Thromb Haemost 2020; 120 (08) 1147-1158
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Tangelder MJ, van Hattum ES. Antithrombotic therapy in peripheral artery disease—antiplatelet therapy, anticoagulants, both or none. Thromb Haemost 2010; 104 (02) 196-199
    PubMedSearch in Google Scholar
  • 9 Bonaca MP, Gutierrez JA, Cannon C. et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol 2018; 6 (12) 934-943
    CrossrefPubMedSearch in Google Scholar
  • 10 Pastori D, Farcomeni A, Milanese A. et al. Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (05) 866-875
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Bonaca MP, Nault P, Giugliano RP. et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 2018; 137 (04) 338-350
    CrossrefPubMedSearch in Google Scholar
  • 12 Jukema JW, Szarek M, Zijlstra LE. et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol 2019; 74 (09) 1167-1176
    CrossrefPubMedSearch in Google Scholar
  • 13 Clavijo LC, Caro J, Choi J. et al. The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study). Cardiovasc Revasc Med 2023; 55: 1-5
    CrossrefPubMedSearch in Google Scholar
  • 14 Sabatine MS, Giugliano RP, Keech AC. et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722
    CrossrefPubMedSearch in Google Scholar
  • 15 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382 (21) 1994-2004
    CrossrefPubMedSearch in Google Scholar
  • 16 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
    CrossrefPubMedSearch in Google Scholar
  • 17 Kaplovitch E, Eikelboom JW, Dyal L. et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol 2021; 6 (01) 21-29
    PubMedSearch in Google Scholar
  • 18 Canonico ME, Hess CN, Naveh S. et al. Real-World Prescription of Dual Pathway Inhibition Therapy in Patients with Peripheral Artery Disease Undergoing Lower Extremity Revascularization. Accessed at: https://cpcclinicalresearch.org/wp-content/uploads/2024/10/SVM-2024-Canonico-Real-World-Prescription-of-Dual-Pathway-Inhibition-Therapy-in-Patients-with-Peripheral-Artery-Disease-Undergoing-Lower-Extremity-Revascularization.pdf
    PubMed
  • 19 Ortega-Paz L, Franchi F, Rollini F. et al. Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) study. Thromb Haemost 2024; 124 (03) 263-273
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Kang DS, Yang PS, Kim D. et al. Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study. Thromb Haemost 2024; 124 (09) 883-892
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects. Thromb Haemost 2024; 124 (09) 842-851
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
    Thieme ConnectPubMedSearch in Google Scholar